Terns Pharmaceuticals, INC

Merck has successfully acquired Terns Pharmaceuticals in a tender offer and subsequent merger, with Terns now operating as a wholly owned subsidiary.

Terns Pharmaceuticals announced its drug candidate TERN-701 has received FDA Breakthrough Therapy Designation for treating chronic myeloid leukemia.

Merck announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, valuing the company at approximately $6.7 billion.

Terns Pharmaceuticals amended its agreement with Hansoh, gaining exclusive worldwide rights to TERN-701 outside the Hansoh Territory for a $1 million upfront fee and tiered royalties.

Terns Pharmaceuticals announced its 2026 priorities and program milestones for TERN-701, alongside a robust unaudited cash position of approximately $1.0 billion extending into 2031.

Terns Pharmaceuticals announced the pricing of an upsized underwritten public offering of common stock, expected to generate approximately $705.8 million in net proceeds to fund its pipeline and extend its cash runway into 2031.

Terns Pharmaceuticals reports strong TERN-701 data and FDA Orphan Drug Designation, while discontinuing its metabolic disease programs to streamline its pipeline.

Terns Pharmaceuticals reports positive clinical data for its lead oncology and obesity programs, extending its cash runway into 2028 while strategically seeking partnerships for metabolic assets.

Terns Pharmaceuticals reports a net loss for Q1 2025, alongside updates on its clinical programs and executive transitions.

Terns Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs and a recent capital raise.

Terns Pharmaceuticals reported a net loss of $22.7 million for the second quarter of 2024, while highlighting progress in its clinical programs and strategic focus on oncology and obesity.

Terns Pharmaceuticals reported a net loss of $22.4 million for the first quarter of 2024, while highlighting progress in its clinical programs and a leadership transition.

Terns Pharmaceuticals filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding executive compensation and corporate governance.

Terns Pharmaceuticals' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including TERN-701 for CML and TERN-601 for obesity.

Terns Pharmaceuticals' 10-K filing details its capital stock, registration rights, and progress in developing treatments for CML and obesity, with cash runway into 2026.

Director Robert Azelby reports the cancellation of stock options following the completion of the merger between Terns Pharmaceuticals and Merck.

Director Heather D. Turner reports the cancellation and cash-out of stock options following the completion of Terns Pharmaceuticals' acquisition by Merck.

Director Radhika Tripuraneni reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director Jill M. Quigley reports the cancellation and conversion of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director Jeffrey B. Kindler reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director David A. Fellows reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Terns Pharmaceuticals has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Terns Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders online on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Terns Pharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

Terns Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders online on June 10, 2024, to elect directors and ratify the selection of its independent accounting firm.

OrbiMed Advisors and its affiliates have significantly reduced their holdings in Terns Pharmaceuticals, Inc., ceasing to be beneficial owners of more than 5% of the company's common stock.

Morgan Stanley has filed an amendment indicating it no longer beneficially owns more than five percent of Terns Pharmaceuticals, Inc. common stock.

Adage Capital Management, L.P. has reported beneficial ownership of 2,124,817 shares, representing 1.84% of Terns Pharmaceuticals, Inc. common stock as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of Terns Pharmaceuticals, Inc. common stock.

The Vanguard Group has amended its Schedule 13G filing for Terns Pharmaceuticals Inc., reporting zero beneficial ownership following an internal realignment.

Vivo Capital entities have filed an Amendment No. 3 to Schedule 13G, disclosing their passive beneficial ownership in Terns Pharmaceuticals, Inc. common stock.

Deep Track Capital and affiliates have reduced their beneficial ownership in Terns Pharmaceuticals, Inc. to 2.97% of common stock.